Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 6:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 684 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: HER2 Negative Breast Carcinoma Clear all
Withdrawn Phase 4 Interventional

A Study of Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer

NCT03988114
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Abemaciclib, Nonsteroidal Aromatase Inhibitor (NSAI)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
70
States / cities
Daphne, Alabama • Tempe, Arizona • Fountain Valley, California + 60 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2019 · Synced Oct 17, 2026, 6:03 AM EDT
Completed Phase 3 Interventional Results available

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

NCT01610284
View directory record Official record
Conditions
Breast Cancer
Interventions
Fulvestrant, BKM120, BKM120 matching placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
61
States / cities
Mobile, Alabama • Phoenix, Arizona • Fayetteville, Arkansas + 51 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2020 · Synced Oct 17, 2026, 6:03 AM EDT
Recruiting Phase 1 Interventional

DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast Cancer

NCT05504707
View directory record Official record
Conditions
Triple Negative Breast Cancer, HER2-negative Breast Cancer
Interventions
HER2 - primed Dendritic cells, HER3 - primed Dendritic cells
Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 17, 2026, 6:03 AM EDT
Recruiting Phase 2 Interventional

Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer

NCT05020860
View directory record Official record
Conditions
Breast Cancer, Breast Neoplasm, Breast Cancer Female, Breast Cancer Invasive, Breast Cancer Stage II, Breast Cancer Stage III, Triple Negative Breast Cancer, Hormone Receptor-positive Breast Cancer, HER2-positive Breast Cancer, Triple Negative Breast Neoplasms, Estrogen Receptor-positive Breast Cancer
Interventions
Paclitaxel, Carboplatin, Trastuzumab, Pertuzumab, Doxorubicin, Cyclophosphamide, Pembrolizumab, Pertuzumab/Trastuzumab/Hyaluronidase-zzxf
Drug
Lead sponsor
Baylor Breast Care Center
Other
Eligibility
18 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 27, 2025 · Synced Oct 17, 2026, 6:03 AM EDT
Not listed Phase 2 Interventional

Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling

NCT03412643
View directory record Official record
Conditions
HER2-negative Breast Cancer
Interventions
Doxorubicin, Cyclophosphamide, Weekly Paclitaxel, Trastuzumab, Pertuzumab, Celcuity CELx HSF
Drug · Diagnostic Test
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older · Female only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
43
States / cities
Colton, California • Miami Beach, Florida • Orlando, Florida + 34 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2023 · Synced Oct 17, 2026, 6:03 AM EDT
Withdrawn Phase 2 Interventional

Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast Cancer

NCT03644589
View directory record Official record
Conditions
Estrogen Receptor Negative, HER2/Neu Negative, Metastatic Breast Cancer, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Triple Negative Breast Cancer
Interventions
Pembrolizumab, Cisplatin
Biological · Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 26, 2019 · Synced Oct 17, 2026, 6:03 AM EDT
Completed Phase 1 Interventional

A Phase I, Multicenter, Open-Label, Multi-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast Cancer

NCT02338349
View directory record Official record
Conditions
Advanced ER+, HER2-Negative Breast Cancer
Interventions
Elacestrant
Drug
Lead sponsor
Stemline Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 18, 2022 · Synced Oct 17, 2026, 6:03 AM EDT
Completed Phase 1 Interventional

Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer

NCT01145430
View directory record Official record
Conditions
Estrogen Receptor Negative, HER2/Neu Negative, Male Breast Carcinoma, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Stage IV Breast Cancer AJCC v6 and v7, Triple-Negative Breast Carcinoma
Interventions
Laboratory Biomarker Analysis, Pegylated Liposomal Doxorubicin Hydrochloride, Pharmacological Study, Veliparib
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
6
States / cities
New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Dec 22, 2017 · Synced Oct 17, 2026, 6:03 AM EDT
Terminated Phase 3 Interventional Results available

A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi

NCT01633060
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Fulvestrant, BKM120, BKM120 matching placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
432 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
37
States / cities
Mobile, Alabama • Chandler, Arizona • Fayetteville, Arkansas + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2019 · Synced Oct 17, 2026, 6:03 AM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer

NCT04214288
View directory record Official record
Conditions
Advanced ER-Positive HER2-Negative Breast Cancer
Interventions
AZD9833, Fulvestrant
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years · Female only
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
9
States / cities
Birmingham, Alabama • Long Beach, California • Fort Myers, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 17, 2026, 6:03 AM EDT
Recruiting Phase 2 Interventional

Molecular Analyses to Predict Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients With Hormone Receptor-Positive HER2-negative Breast Cancer

NCT06361940
View directory record Official record
Conditions
Breast Cancer
Interventions
Aromatase inhibitors or tamoxifen
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 17, 2026, 6:03 AM EDT
Terminated Phase 2 Interventional

Tesetaxel Plus Reduced Dose of Capecitabine in Patients With HER2 Negative, HR Positive, LA/MBC

NCT03858972
View directory record Official record
Conditions
Breast Cancer
Interventions
Tesetaxel, Capecitabine
Drug
Lead sponsor
Odonate Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
9
States / cities
Whittier, California • Lakewood, Colorado • Fort Myers, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2021 · Synced Oct 17, 2026, 6:03 AM EDT
Active, not recruiting Phase 2 Interventional

Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer

NCT04762979
View directory record Official record
Conditions
Hormone Receptor Positive Breast Carcinoma, HER2-negative Breast Cancer, PIK3CA Mutant Metastatic Breast Cancer
Interventions
Alpelisib, Fulvestrant, Aromatase inhibitor
Drug
Lead sponsor
Marina N Sharifi
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
4
States / cities
Chicago, Illinois • Omaha, Nebraska • Hershey, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2026 · Synced Oct 17, 2026, 6:03 AM EDT
Completed Phase 2 Interventional Results available

Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery

NCT00861705
View directory record Official record
Conditions
Male Breast Carcinoma, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Triple-Negative Breast Carcinoma
Interventions
Bevacizumab, Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
454 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2025
U.S. locations
448
States / cities
Jonesboro, Arkansas • Rogers, Arkansas • Berkeley, California + 309 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 17, 2026, 6:03 AM EDT
Recruiting No phase listed Observational

Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastases

NCT07619534
View directory record Official record
Conditions
Breast Cancer, Breast Carcinoma, Cancer of the Breast, Malignant Neoplasm of Breast
Interventions
Arm 1
Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 17, 2026, 6:03 AM EDT
Terminated Phase 2 Interventional Results available

Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study)

NCT04738292
View directory record Official record
Conditions
ER-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Cancer
Interventions
Onapristone, Fulvestrant
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Madison, Wisconsin • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 3, 2024 · Synced Oct 17, 2026, 6:03 AM EDT
Active, not recruiting Phase 1 Interventional

Cyclophosphamide and Veliparib in Treating Patients With Locally Advanced or Metastatic Breast Cancer

NCT01351909
View directory record Official record
Conditions
Locally Advanced Unresectable Breast Carcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
Interventions
Cyclophosphamide, Laboratory Biomarker Analysis, Veliparib
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2027
U.S. locations
5
States / cities
New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 17, 2026, 6:03 AM EDT
Terminated Phase 2 Interventional Results available

Nintedanib For HER2-Negative Metastatic Inflammatory Breast Cancer (MIBC)

NCT02389764
View directory record Official record
Conditions
Breast Cancer
Interventions
BIBF 1120, Phone Call
Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 17, 2019 · Synced Oct 17, 2026, 6:03 AM EDT
Active, not recruiting Phase 2 Interventional

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

NCT05826964
View directory record Official record
Conditions
Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer
Interventions
AI+CDK4/6i, SERD+CDK4/6i, mTOR inhibitor + AI, mTOR inhibitor + SERD, mTOR inhibitor + Selective estrogen receptor modulator, PI3K inhibitor + SERD, PI3K inhibitor + AI, Chemotherapy, Oral SERD, PARPi, AKT inhibitor, Step 3 Arm 2
Drug · Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 17, 2026, 6:03 AM EDT
Completed Not applicable Interventional Results available

DWI in Assessing Treatment Response in Patients With Breast Cancer Receiving Neoadjuvant Chemotherapy

NCT01564368
View directory record Official record
Conditions
Breast Cancer
Interventions
diffusion-weighted magnetic resonance imaging
Procedure
Lead sponsor
American College of Radiology Imaging Network
Network
Eligibility
18 Years and older · Female only
Enrollment
406 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
7
States / cities
Birmingham, Alabama • San Francisco, California • Minneapolis, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2024 · Synced Oct 17, 2026, 6:03 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Onvansertib + Paclitaxel In TNBC

NCT05383196
View directory record Official record
Conditions
Breast Cancer, Invasive Breast Cancer, Unresectable Breast Carcinoma, Locally Advanced Breast Cancer, Metastatic Breast Cancer, Inflammatory Breast Cancer, Triple Negative Breast Cancer (TNBC), Hormone Receptor/Growth Factor Receptor-Negative Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Negative Breast Carcinoma
Interventions
Onvansertib, Paclitaxel
Drug
Lead sponsor
Antonio Giordano, MD
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Oct 17, 2026, 6:03 AM EDT
Completed Phase 2 Interventional Results available

Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer

NCT01698918
View directory record Official record
Conditions
Hormone Receptor Positive Breast Cancer
Interventions
Everolimus, Letrozole, Exemestane, Alcohol-free dexamethasone mouth rinse (Stomatitis sub-study), Standard of care to treat stomatitis (Stomatitis sub-study)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
15
States / cities
Birmingham, Alabama • Gilbert, Arizona • Loma Linda, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 3, 2023 · Synced Oct 17, 2026, 6:03 AM EDT
Active, not recruiting Phase 2 Interventional

Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)

NCT06428396
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Belzutifan, Fulvestrant, Everolimus, Exemestane
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
14
States / cities
Goodyear, Arizona • Beverly Hills, California • La Jolla, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 17, 2026, 6:03 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

NCT04915755
View directory record Official record
Conditions
Neoplasms, Breast
Interventions
Niraparib, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
24
States / cities
Burbank, California • Duarte, California • Palo Alto, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Oct 17, 2026, 6:03 AM EDT